Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach

Despite the observed clinical benefits of nirmatrelvir/ritonavir (NMV/r), it is uncertain whether Taiwan will continue covering NMV/r for high-risk individuals with mild-to-moderate coronavirus disease 2019 (COVID-19). This analysis assessed the impact of sustained utilization of NMV/r on COVID-19-a...

Full description

Bibliographic Details

Published in:	Journal of Market Access & Health Policy
Main Authors:	Matthew Sussman, Jennifer Benner, Tendai Mugwagwa, Jackie Lee, Sheng-Tzu Hung, Ya-Min Yang, Yixi Chen
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Subjects:	coronavirus disease 2019 COVID-19 nirmatrelvir nirmatrelvir/ritonavir clinical burden model
Online Access:	https://www.mdpi.com/2001-6689/12/4/26